hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06280222 id: VR FOR ANXIETY-HMO-CTIL briefTitle: The Effectiveness of Virtual Reality on Anxiety Reduction in Women Undergoing Elective Egg Cryopreservation. acronym: VRFORANXIETY overallStatus: RECRUITING date: 2023-11-15 date: 2024-11-15 date: 2025-02-01 date: 2024-02-28 date: 2024-02-28 name: Hadassah Medical Organization class: OTHER briefSummary: A randomized trial assessing the effectiveness of virtual reality exposure prior to an oocyte retrieval procedure in terms of anxiety level . conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 30 type: ESTIMATED name: The VR instrument - Oculus Quest 2 measure: Vital signs measure: Vital signs measure: VAS (visual-analogue scale) measure: State and Trait Anxiety (STAI) Score sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Hadassah mound scopus IVF unit status: RECRUITING city: Jerusalem country: Israel name: Anat Hershko-Klement, M.D role: CONTACT phone: +972549170084 email: anat.klement@gmail.com lat: 31.76904 lon: 35.21633 hasResults: False
nctId: NCT06280209 id: 351-201 id: 2023-506737-30-00 type: OTHER domain: EU CT briefTitle: A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy overallStatus: RECRUITING date: 2024-01-03 date: 2025-12 date: 2025-12 date: 2024-02-28 date: 2024-04-16 name: BioMarin Pharmaceutical class: INDUSTRY briefSummary: The purpose of this study is to test the safety and tolerability of BMN 351 in participants with Duchenne Muscular Dystrophy (DMD) with a genetic mutation amenable to exon 51 skipping. conditions: Duchenne Muscular Dystrophy studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: BMN 351 measure: To evaluate and safety and tolerability of single and multiple doses of BMN 351 (incidence, severity, and dose-relationship of adverse effects and changes in laboratory parameters). measure: Pharmacokinetics (PK) concentration of BMN 351 in plasma, urine and muscle approximately every 8 weeks for up to 48 weeks. measure: To evaluate the immune response to BMN 351. measure: To evaluate the effect of BMN 351 on physical function. measure: To evaluate the effect of BMN 351 on physical function. measure: Change from baseline in dystrophin expression measured by Liquid chromatography-mass spectrometry (LC-MS). sex: MALE minimumAge: 4 Years maximumAge: 10 Years stdAges: CHILD facility: Hospital Sant Joan de Deu status: RECRUITING city: Barcelona zip: 08950 country: Spain name: Soraya Peralta role: CONTACT phone: +34 673200068 email: soraya.peralta@sjd.es name: Andres Nascimento role: PRINCIPAL_INVESTIGATOR lat: 41.38879 lon: 2.15899 facility: Hospital Viamed Santa Angela De la Cruz status: RECRUITING city: Sevilla zip: 41013 country: Spain name: Carmen Silva role: CONTACT phone: +34 669393637 email: tuautorapreferida@gmail.com name: Marcos Madruga-Garrido role: PRINCIPAL_INVESTIGATOR lat: 37.38283 lon: -5.97317 facility: Great Ormond Street Hospital NHS Foundation Trust status: RECRUITING city: London zip: WC1N 3JH country: United Kingdom name: Marta Zancolli role: CONTACT phone: +44 (0)20 7905 2188 email: marta.zancolli@gosh.nhs.uk name: Giovanni Baranello role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06280196 id: BAT-3306-002-CR briefTitle: A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC overallStatus: NOT_YET_RECRUITING date: 2024-08-15 date: 2027-07-30 date: 2028-10-30 date: 2024-02-28 date: 2024-03-25 name: Bio-Thera Solutions class: INDUSTRY briefSummary: To compare the pairwise PK similarities between BAT3306, EU-Keytruda, and US-Keytruda, all administered with pemetrexed and carboplatin. conditions: Carcinoma, Non-Small-Cell Lung studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: double-blind, randomized primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 676 type: ESTIMATED name: BAT3306 name: EU-Keytruda® name: US-Keytruda® name: Pemetrexed name: Carboplatin measure: clinical equivalence measure: safety of BAT3306-AE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06280183 id: 323132 briefTitle: Functional Inspiratory Muscle Training in Obese Individuals overallStatus: NOT_YET_RECRUITING date: 2024-02-28 date: 2025-06-30 date: 2025-06-30 date: 2024-02-28 date: 2024-02-28 name: Biruni University class: OTHER name: Istanbul Galata University briefSummary: In obese individuals, increased adipose tissue and systemic inflammation play a key role in the development of cardiometabolic diseases, pulmonary system dysfunction, and many respiratory diseases. Existing research has demonstrated beneficial clinical outcomes of inspiratory muscle training or combined aerobic and resistance exercise training in obese individuals. However, this focused on the isolated effects of exercise on obesity. In the current literature, no study is evaluating the effectiveness of functional inspiratory muscle training in obese individuals.
This study aims to investigate the effects of functional inspiratory muscle training on body composition, cardiometabolic markers, functional capacity, respiratory function, respiratory muscle strength, and respiratory muscle performance in obese individuals. conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a randomized, single-blind study three arm study. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: The assessor will be blind to the group allocation, and participants will be blind to group allocation whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: Functional Inspiratory Muscle Training name: Aerobic+Resistive Exercise Traning measure: Respiratory Muscle Strength measure: Incremental load test (Respiratory Muscle Endurance) measure: Forced expiratory volume 1st second (Respiratory Function) measure: Forced vital capacity (Respiratory Function) measure: Comorbidity Assessment measure: Physical Activity Assessment measure: Edmonton Obesity Staging System (EOSS) measure: Functional Capacity measure: Peripheral Muscle Strength measure: Waist circumference measure: Hip circumference measure: Body fat-muscle ratios measure: Glucose profile measure: Lipid profile sex: ALL minimumAge: 25 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06280170 id: ST11480 briefTitle: AI to Support Mental Health Case Management Providers overallStatus: ENROLLING_BY_INVITATION date: 2024-02-19 date: 2025-06-30 date: 2025-12-31 date: 2024-02-28 date: 2024-02-28 name: Eleos Health class: INDUSTRY name: Centerstone Research Institute briefSummary: The goal of this clinical trial is to assess the effectiveness of an artificial intelligence (AI) platform for case managers in a nonprofit health system specializing in mental health and substance use disorder. The main questions it aims to answer are:
2. Does the AI platform improve providers' productivity and reported interventions? Participants will be approximately 30 case managers and their 250 adult clients receiving case management services. Researchers will compare the provider productivity and work satisfaction prior to the implementation of the AI platform to following its implementation. conditions: Depressive Disorder conditions: Anxiety Disorders conditions: Substance Use Disorders conditions: Post Traumatic Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: This study will follow a stepped-wedge, randomized controlled design, where each provider team will undergo two phases: SAU and the AI platform phase. All teams will initially start with SAU, and the AI platform will be sequentially introduced to teams over time. Teams will be randomly assigned to different time periods for the AI platform phase using simple randomization. The order of implementation will be determined by randomly selecting the number of the team from sealed envelopes every two months. In both phases, the study will enroll new and existing clients. At the end of the trial all teams would have used Eleos for a few months primaryPurpose: OTHER masking: NONE maskingDescription: The masking in this study involves a differential approach between providers and clients. Providers will be aware of whether they are in the Services-As-Usual (SAU) or Artificial Intelligence (AI) phase. However, participating clients will not be informed about the platform their provider is using to document their therapy sessions. count: 280 type: ESTIMATED name: Artificial Intelligence platform for case managers measure: Case manager satisfaction measure: Case manager productivity measure: Case manager note completion time measure: Clients' crisis services utilization sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centerstone city: Alton state: Illinois zip: 62002 country: United States lat: 38.8906 lon: -90.18428 hasResults: False
nctId: NCT06280157 id: MVX0007 id: 332126 type: OTHER domain: IRAS briefTitle: A Follow up Study of Group B Streptococcus Vaccine (GBS-NN/NN2 Vaccine) in Healthy Volunteers overallStatus: ENROLLING_BY_INVITATION date: 2024-01-18 date: 2028-01 date: 2028-01 date: 2024-02-28 date: 2024-02-28 name: Minervax ApS class: OTHER name: Simbec-Orion Group briefSummary: The goal of this follow-up study is to investigate the persistence of the immune response induced by the GBS-NN/NN2 vaccine in women who have participated in study MVX0002, and/or in study MVX0003 with GBS-NN/NN2 vaccine and received 1, 2 or 3 doses of GBS-NN/NN2. The main question it aims to answer is to determine the persistence of the immune response induced by the GBS-NN/NN2 vaccine by measuring antibody concentrations.
Participants who had received a primary course of GBS-NN/NN2 in Study MVX0002 and/or MVX0003 will be invited to return to have a single yearly blood sample of approximately 10 mL collected 2 to 5 years after the completion of the previous vaccination. conditions: Group B Streptococcus Infection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 55 type: ESTIMATED name: GBS-NN/NN2 measure: Antibody Concentration Specific for GBS-NN and GBS-NN2 measure: Antibody Responses Specific to AlpCN, RibN, Alp1N and Alp2-3N sex: FEMALE minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Simbec-Orion Clinical Pharmacology city: Merthyr Tydfil state: Pentrebach Merthyr Tydfil CF48 4DR country: United Kingdom lat: 51.74794 lon: -3.37779 hasResults: False
nctId: NCT06280144 id: PF20230428 briefTitle: Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine overallStatus: RECRUITING date: 2023-09-22 date: 2024-06-30 date: 2024-10-30 date: 2024-02-28 date: 2024-02-28 name: Changchun BCHT Biotechnology Co. class: INDUSTRY name: Hu Bei province Center for Disease control and prevention name: The Inner Mongolia Autonomous Region Center for Disease Control and Prevention briefSummary: To evaluate the protective effect 14 days after the live attenuated influenza vaccine; To evaluate the protective effect of vaccination with live attenuated influenza vaccine; To evaluate the safety of freeze-dried nasal spray live attenuated influenza vaccine; To evaluate the detoxification and genetic stability of lyophilized nasal spray vaccine.
To evaluate the protective effect of novel coronavirus after 14 days of inoculation with the live attenuated influenza vaccine. conditions: Influenza Prevention studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 6080 type: ESTIMATED name: Influenza Vaccine, Live, Nasal, Freeze-dried name: Sterile water for inhalation measure: Primary influenza protective effect endpoint measure: Primary influenza protective effect endpoint measure: Secondary protective efficacy endpoint measure: Secondary protective efficacy endpoint measure: Secondary protective efficacy endpoint measure: Safety measure: Study on detoxification measure: Protective effect of COVID-19 cases. sex: ALL minimumAge: 3 Years maximumAge: 17 Years stdAges: CHILD status: RECRUITING city: Chi Feng state: Inner Mongolia Autonomous Region zip: 024000 country: China name: Xiaoling Tian role: CONTACT phone: 13848710296 email: txlingok@126.com hasResults: False
nctId: NCT06280131 id: multiple sclerosis and pulse briefTitle: The Efficacy of Pulse Therapy in Acute Relapse in Multiple Sclerosis Patients: overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-03-01 date: 2025-04-01 date: 2024-02-28 date: 2024-02-28 name: Assiut University class: OTHER briefSummary: This work is aimed to assess the short term effect of pulse therapy on clinical and neurophysiological course before and after pulse therapy in order to understand the possible mechanism of action of steroid therapy on RRMS patients low-dose oral treatment should also be retained for patients in whom this approach seems appropriate conditions: Multiple Sclerosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED measure: to evaluate efficacy of a pulse therapy on clinical outcome measure: clinical correlation between clinical scales scores and neurophysiological changes(visual evoked potional measure: clinical correlation between clinical scales scores and neurophysiological changes( cortical exitability parameters) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06280118 id: EFCPR008 briefTitle: The Effect of Fatigue on CPR overallStatus: COMPLETED date: 2023-04-20 date: 2023-06-20 date: 2023-10-25 date: 2024-02-28 date: 2024-02-28 name: Artvin Coruh University class: OTHER briefSummary: Background: This study, in contrast to the previous studies, generated a scenario of fatigue in an earthquake scenario and aimed to measure the effect of fatigue on the quality of cardiopulmonary resuscitation (CPR) performed by paramedics in a debris course.
Methods: The study was designed as a randomized controlled trial. The sample, consisting of 84 paramedic students, was randomly assigned as 42 control and 42 experimental groups. Fatigue was created in the participants by rehearsing the process of removing and transporting earthquake victims from the rubble through the prepared track. A personal information form and a CPR measurement form were used to obtain the data. The simulator was used to evaluate the accuracy of CPR. The collected data were analysed with the statistical program. conditions: Resuscitation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled trial primaryPurpose: SCREENING masking: NONE count: 84 type: ACTUAL name: Fatigue measure: Correct number of ventilations measure: Correct number of compression measure: CPR duration sex: ALL minimumAge: 18 Years maximumAge: 24 Years stdAges: ADULT facility: Resuscitation simulation laboratory of Artvin Çoruh University Health Services Vocational School city: Artvin zip: 08000 country: Turkey lat: 41.18161 lon: 41.82172 hasResults: False
nctId: NCT06280105 id: 2023_148_01 briefTitle: A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2026-03-31 date: 2027-03-31 date: 2024-02-28 date: 2024-02-28 name: Meng Chao Hepatobiliary Hospital of Fujian Medical University class: OTHER briefSummary: To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib. conditions: Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Cadonilimab+regorafenib measure: objective response rate (ORR) per RECIST1.1 measure: Progression-free survival（PFS） measure: Overall survival（OS） measure: Duration of response (DOR) measure: Occurence of AE and SAE sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mengchao Hepatobiliary Hospital, Fujian Medical University city: Fuzhou state: Fujian country: China lat: 26.06139 lon: 119.30611 hasResults: False
nctId: NCT06280092 id: 23-009133 briefTitle: Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-03 date: 2025-03 date: 2024-02-28 date: 2024-04-08 name: Sanjeet S. Grewal class: OTHER briefSummary: This study is a non-randomized, open label, phase 1 clinical trial to evaluate the fesibility and safety of intrathalamic delivery of MSCs during standard of care DBS surgery for epilepsy.
Subjects will be screened at our outpatient clinic and interested qualified subjects will be consented and offered participation in this trial. Once consent has been obtained, patients will undergo a standard preoperative evaluation which includes baseline laboratory values and a high-definition MRI. Patients will then undergo a stereotactic procedure for bilateral thalamic implantation of DBS leads through the ClearPoint® system. After the thalamic target for DBS is identified, cells will be infused directly into the anterior nucleus of the thalamus previous to lead implantation.
Surgical, clinical, and radiographic data will be obtained during these visits conditions: Epilepsy studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A single dose of 5x10\^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery primaryPurpose: OTHER masking: NONE maskingDescription: This is an unmasked study count: 5 type: ESTIMATED name: AMSCs measure: Primary Objective measure: Secondary Objective sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06280053 id: 103-3024A3 briefTitle: HealiAid in the Treatment of Different Wounds overallStatus: COMPLETED date: 2016-03-02 date: 2018-04-11 date: 2018-10-26 date: 2024-02-28 date: 2024-02-28 name: Maxigen Biotech Inc. class: INDUSTRY briefSummary: The goal of this open-label, post-market clinical follow-up study is to demonstrate the safety and effectiveness of HealiAid Collagen Wound Dressing in patients classified into different types of wounds: venous ulcers, bedsores, diabetic foot wounds and burn wounds.
HealiAid will be applied to eligible subjects who will later be followed up for 12 weeks. conditions: Venous Ulcers conditions: Bedsores conditions: Diabetic Foot Wound conditions: Burn Wound studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The patients' wound conditions were divided into four types: venous ulcers, bedsores, diabetic foot wounds and burn wounds. primaryPurpose: OTHER masking: NONE count: 18 type: ACTUAL name: HealiAid Collagen Wound Dressing measure: Wound Healing measure: Wound Healing measure: Duration of Wound Healing measure: Granulation Tissue Growth measure: Wound Exudate measure: Incidence of Safety Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06280040 id: UM Longitudinal 1942/2022 briefTitle: Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma overallStatus: RECRUITING date: 2023-11-23 date: 2025-06-30 date: 2025-06-30 date: 2024-02-28 date: 2024-03-06 name: Medical University of Vienna class: OTHER briefSummary: The purpose of this study is to evaluate the incidence and severity of retinopathy and opticopathy one year after treatment with hypofractionated stereotactic photon radiotherapy due to uveal melanoma. Patients will be imaged before radiation, as well as 3, 6, 9 and 12 months after radiation using sonography funds photography, optical coherence tomography angiography, oximeter and microperimetry. conditions: Uveal Melanoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Clinical examination and multimodal ocular imaging measure: Incidence and Severity of Retinopathy measure: Incidence and Severity of Opticopathy measure: Functional Outcome measure: Incidence and Severity of Retinopathy and Opticopathy in oximeter sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Ophthalmology and Optometry, Medical University Vienna status: RECRUITING city: Vienna zip: 1090 country: Austria name: Judith Kreminger, MD role: CONTACT phone: 0043 1 40400 48470 email: judith.kreminger@meduniwien.ac.at name: Reinhard Told, MD, PhD, Priv.-Doz. role: CONTACT phone: 0043 1 40400 48470 email: reinhard.told@meduniwien.ac.at name: Adrian Reumueller, MD, Priv.-Doz role: SUB_INVESTIGATOR name: Roman Dunavoelgyi, MD, Assoc.-Prof. role: SUB_INVESTIGATOR lat: 48.20849 lon: 16.37208 hasResults: False
nctId: NCT06280027 id: MUDHF_BK1 briefTitle: Effect of Midline Discrepancy and Crown Width Disporportion on Esthetics overallStatus: COMPLETED date: 2023-06-05 date: 2023-06-12 date: 2023-12-22 date: 2024-02-28 date: 2024-02-28 name: Marmara University class: OTHER briefSummary: In the web-based cross-sectional study 180 participants were included. Half of them (n = 90) were patients (laypeople) of the university clinic and the remaining half were restorative dentists and prosthodontists with similar levels of clinical experience (at least 3 years of academic training).
In total, 15 images were displayed in random order to the participants including the original image. An online survey was generated to quantitatively evaluate the level of esthetic perception. Subsequently, the participants were asked to evaluate the level of smile esthetics of the presented random images, without being informed about the digital manipulations of the images. The participants were even not informed about the original image. They were expected to answer the question "How esthetic do you consider this smile?" The evaluation of each image was performed via a Visual analog scale VAS, ranging from point 0 (extremely not esthetic) to point 100 (extremely esthetic). conditions: Esthetics, Dental studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 180 type: ACTUAL name: survey measure: survey on midline discrepancy at different levels measure: survey on individual crown width disproportions measure: survey on distributed crown width disproportions sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Marmara University Faculty of Dentistry city: İstanbul zip: 34854 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False